Skip to main content
Research Paper Graduate 1,893 words

Tissue Tracking Deficiencies and Patient Safety Risks

~10 min read 6 sections Health · Patient Safety
Abstract

This paper evaluates systemic deficiencies in tissue tracking systems used by surgical departments and organ procurement organizations, and their consequences for patient safety. Drawing on CDC and FDA investigations, case studies of hepatitis C transmission through transplanted tissues, and professional policy recommendations, the paper identifies the two primary ongoing threats: tissues that go unaccounted during recalls and dangerous delays in recall notification. The paper reviews regulatory standards established by the Joint Commission, FDA, and ICCBBA, examines documented failures spanning 1985 to 2013, and argues that despite more than a decade of patient safety reforms, both procurement organizations and surgical departments must do substantially more to close existing knowledge and procedural gaps.

Key Takeaways
  • Introduction: Regulatory background and rationale for tissue tracking standards
  • What Can Go Wrong?: 2011 CDC hepatitis C case study and screening failures
  • Documented Failures and Their Consequences: Historical recall incidents and unaccounted tissue data
  • Discussion: Key Deficiencies in Tissue Tracking: Documentation gaps and minimum regulatory requirements
  • Knowledge Gaps: Unresolved notification and international tracking gaps
  • Conclusions: Two core ongoing threats to patient safety identified
✍️ How to write this paper — guide, tools & examples ▾

What makes this paper effective

  • Grounds abstract policy concerns in concrete, well-documented case studies — including the 2011 CDC hepatitis C investigation — giving the argument real-world credibility and urgency.
  • Moves logically from regulatory background to failure analysis to knowledge gaps, creating a coherent problem-statement structure that clearly identifies two actionable priorities.
  • Uses quantitative data effectively (e.g., 61,607 tissue allografts recalled between 1994 and 2007; 2.5–9.0% tracking deficiency rates) to convey the scale of risk without overstating conclusions.

Key academic technique demonstrated

The paper demonstrates systematic problem framing: it narrows a broad patient-safety topic to two specific, researchable gaps — unaccounted tissues and notification delays — and distinguishes these from the related but separate issue of testing accuracy. This scoping technique is essential in graduate-level health policy writing, signaling analytical precision rather than unfocused survey coverage.

Structure breakdown

The paper opens with regulatory context (Joint Commission, FDA, ICCBBA standards), then catalogs documented failures through case studies and aggregate recall data. A discussion section synthesizes the practical deficiencies identified in the literature, followed by a knowledge gaps section identifying areas requiring further study. The conclusion returns to the two core problems and calls for action by procurement organizations and surgical departments alike.

Essay 1,893 words

Introduction

The Joint Commission established standards for the handling of tissues in allograft procedures in 2005 (Meeting JCAHO's new tissue standards, 2005). The three main areas of concern were creating a standardized process for handling tissues, investigating adverse events, and tracking tissue from donor to recipient. The details of these rules can be found on the U.S. Food and Drug Administration website (FDA, 2013). The International Council for Commonality in Blood Banking Automation (ICCBBA, 2013) has produced a set of international coding standards for medical products derived from humans, including blood, tissues, organs, milk, cellular therapy products, and plasma products that must be ABO typed before use. These standards are used in more than 75 nations on six continents (ICCBBA, 2013). Government and healthcare provider accrediting agencies are therefore allocating significant resources to the issue of tissue tracking. For example, a Joint Commission survey of the Charleston Area Medical Center in Charleston, West Virginia in 2006 investigated every step of the tissue tracking procedures the hospital used, from arrival to storage to peri-surgical entry into the patient's chart (Tissue tracking requirements, 2007).

In light of a health system-wide push to improve patient safety and reduce the cost of healthcare services, it seems unlikely that the many rules and regulations governing the allograft documentation trail are frivolous. To better understand the rationale behind these rules and regulations, the research literature, policy statements, and professional opinions relevant to this topic are reviewed here.

5 Sections Hidden · 1,265 words
What Can Go Wrong?320 words
In 2011, the U.S. Centers for Disease Control and Prevention (CDC) issued a report revealing…
Documented Failures and Their Consequences420 words
The Chief Policy Officer of the American Association of Tissue Banks, Scott Brubaker (2010), listed several other incidents in which tissue tracking failed to meet expectations. Donor screening in 1991 failed to detect HIV in a donor…
Discussion: Key Deficiencies in Tissue Tracking195 words
The main deficiencies existing in the donor-recipient pathway are testing sensitivity and accuracy, poor documentation by end-users, and notification delays by tissue and organ procurement agencies and surgical departments. The problem examined here is not focused on testing accuracy, but…
Knowledge Gaps145 words
While these rules, regulations, and recommendations will help protect patient safety, CDC and FDA investigations have revealed that they are not sufficient to bring the risk of transmission or contamination to acceptable levels. For this to occur, both tissue banks and end-users must improve…
Conclusions185 words
Poorly implemented and designed tissue tracking systems used by some surgical departments and tissue procurement organizations represent a major threat to patient safety. While there may have been a slight improvement in the number…

References

Brubaker, S. A. (2010). Tissue tracking failures and lessons learned: Hope for the future. Retrieved April 15, 2014, from

CDC. (2011). Transmission of hepatitis C virus through transplanted organs and tissue: Kentucky and Massachusetts, 2011. Morbidity and Mortality Weekly Report, 60(50), 1697–1700.

FDA. (2013). Vaccines, blood & biologics: Biologics rules. Retrieved April 15, 2014, from http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ActsRulesRegulations/default.htm

Giachetta-Ryan, D. (2008). On the trail of tissue tracking. OR Nurse, 2(9), 27–29.

ICCBBA. (2010). What is ISBT 128? Retrieved April 15, 2014, from

ICCBBA. (2013). ISBT 128 standard technical specification (version 4.5.0). ICCBBA ST-001. San Bernardino, CA: ICCBBA.

Mahajan, R., & Kuehnert, M. J. (2013). How can we improve tracking of transplanted tissue in the United States? Cell and Tissue Banking. Published online November 27, 2013, ahead of print.

Meeting JCAHO's new tissue standards. (2005). OR Manager, 21(6), 1–4.

Strong, D. M., & Shinozaki, N. (2010). Coding and traceability for cells, tissues and organs for transplantation. Cell and Tissue Banking, 11(4), 305–323.

Tissue-tracking requirements: Putting all the pieces together. (2007). OR Manager, 23(2), 1, 15, 17.

Warwick, R. M., Chapman, J., Pruett, T. L., & Wang, H. (2013). Globally consistent coding systems for medical products of human origin. Bulletin of the World Health Organization, 91(5), 314–314A.

Key Concepts in This Paper
Tissue Tracking Allograft Safety Donor Screening Hepatitis C Transmission Recall Notification FDA Oversight Nucleic Acid Testing Procurement Organizations ICCBBA Standards Patient Safety
Cite This Paper
PaperDue. (2026). Tissue Tracking Deficiencies and Patient Safety Risks. PaperDue. https://www.paperdue.com/study-guide/tissue-tracking-deficiencies-patient-safety-188196

Always verify citation format against your institution’s current style guide requirements.